



# Exploring the Role of Oxidative Stress in the Pathophysiology of Metabolic Syndrome: Implications for Therapeutic Targeting

Mugisha Byaruhanga P.

Faculty of Medicine Kampala International University Uganda

## ABSTRACT

Metabolic syndrome (MetS) is a cluster of metabolic abnormalities, including central obesity, insulin resistance, hypertension, dyslipidemia, and pro-inflammatory states, which significantly increase the risk of cardiovascular diseases, type 2 diabetes, and other complications. Emerging evidence suggests that oxidative stress plays a critical role in the pathophysiology of MetS by exacerbating inflammation, impairing insulin signaling, and promoting cellular dysfunction. Oxidative stress, defined as an imbalance between the production of reactive oxygen species (ROS) and the body's antioxidant defenses, contributes to the development and progression of metabolic abnormalities that characterize MetS. This review examines the role of oxidative stress in MetS, focusing on its impact on insulin resistance, endothelial dysfunction, adiposity, and inflammatory responses. Additionally, it explores potential therapeutic approaches aimed at modulating oxidative stress, including the use of antioxidants, lifestyle interventions, and pharmacological agents. Although antioxidant therapies have shown promise, challenges such as the safe and effective use of antioxidants in clinical settings, as well as the complex interactions between oxidative stress and other pathophysiological processes, remain. This article provides a comprehensive overview of the role of oxidative stress in MetS and highlights potential therapeutic strategies to mitigate its effects, offering insights into future research directions in this area.

**Keywords:** Oxidative stress, Metabolic syndrome, Insulin resistance, Inflammation, Therapeutic targeting

## INTRODUCTION

Metabolic syndrome (MetS) is a global public health concern, affecting a significant portion of the adult population worldwide [1]. Characterized by a combination of risk factors including central obesity, dyslipidemia, hypertension, insulin resistance, and chronic low-grade inflammation, MetS increases the risk of developing cardiovascular disease, type 2 diabetes, and other metabolic disorders [1]. The exact mechanisms underlying MetS are complex, involving genetic, environmental, and lifestyle factors. One key factor implicated in the development and progression of MetS is oxidative stress [2]. Oxidative stress refers to the imbalance between the production of reactive oxygen species (ROS) and the body's ability to neutralize them with antioxidants [3]. ROS are highly reactive molecules that can cause damage to cellular structures, including lipids, proteins, and DNA [4]. Under normal physiological conditions, ROS are generated as a byproduct of cellular metabolism, particularly in the mitochondria [4]. However, excessive ROS production, often triggered by factors such as poor diet, obesity, physical inactivity, and environmental toxins, leads to oxidative stress [5]. This chronic oxidative environment contributes to the pathophysiology of MetS by impairing insulin sensitivity, promoting inflammation, and facilitating the development of other metabolic

disturbances. This review aims to explore the role of oxidative stress in the pathophysiology of MetS, examining its impact on various components of the syndrome and discussing therapeutic strategies targeting oxidative stress.

### **The Role of Oxidative Stress in Metabolic Syndrome**

Oxidative stress plays a pivotal role in the development and progression of metabolic syndrome (MetS), a multifactorial condition associated with an increased risk of cardiovascular diseases, type 2 diabetes, and other chronic diseases [6]. The pathophysiology of MetS is complex, involving several interconnected processes, including insulin resistance, inflammation, dyslipidemia, and endothelial dysfunction [7]. At the heart of these processes lies the imbalance between the production of reactive oxygen species (ROS) and the body's ability to neutralize them with antioxidants. ROS, such as superoxide anion ( $O_2^{\bullet-}$ ), hydrogen peroxide ( $H_2O_2$ ), and hydroxyl radicals ( $OH^{\bullet}$ ), are generated during normal cellular metabolism, particularly within the mitochondria [8]. However, when ROS production exceeds the body's antioxidant capacity, oxidative stress occurs, leading to cellular damage and dysfunction [9]. The following sections explore how oxidative stress contributes to various components of MetS, including insulin resistance, inflammation, endothelial dysfunction, and adiposity.

#### **Insulin Resistance and Oxidative Stress**

Insulin resistance is a key feature of MetS, where tissues such as muscle, liver, and adipose tissue become less responsive to insulin, resulting in impaired glucose uptake and elevated blood glucose levels [6]. Oxidative stress has been recognized as a crucial factor in the development of insulin resistance. ROS interfere with insulin signaling pathways, which are essential for regulating glucose homeostasis [10]. One of the major mechanisms by which ROS induce insulin resistance is through the activation of serine kinases such as c-Jun N-terminal kinase (JNK) and I $\kappa$ B kinase (IKK) [11]. These kinases phosphorylate insulin receptor substrates (IRS), which are essential for insulin signaling [12]. Phosphorylation of IRS proteins at serine residues inhibits their ability to transmit signals from the insulin receptor, thereby impairing glucose uptake in target tissues [12]. For example, the activation of JNK by ROS leads to the phosphorylation of IRS-1, which inhibits its function and impairs insulin signaling, contributing to the development of insulin resistance [13]. Additionally, oxidative stress triggers the accumulation of advanced glycation end products (AGEs) in tissues, which further exacerbate insulin resistance. AGEs form when excess glucose binds to proteins, lipids, or nucleic acids, generating highly reactive compounds [14]. AGEs interact with their receptor, RAGE, on various cell types, including endothelial cells and macrophages, leading to the activation of inflammatory pathways and the production of more ROS [15]. This creates a vicious cycle of oxidative damage, inflammation, and insulin resistance, driving the progression of MetS.

#### **Inflammation and Oxidative Stress**

Chronic low-grade inflammation is a hallmark of MetS and is closely linked to oxidative stress. ROS play a central role in triggering and sustaining inflammation by activating key inflammatory pathways. One of the primary pathways activated by oxidative stress is the nuclear factor kappa-light-chain-enhancer of activated B cells (NF- $\kappa$ B) pathway [16]. NF- $\kappa$ B is a transcription factor that regulates the expression of various pro-inflammatory cytokines, such as tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), interleukin-6 (IL-6), and interleukin-1 $\beta$  (IL-1 $\beta$ ) [17]. These cytokines are involved in the inflammatory response and contribute to insulin resistance, endothelial dysfunction, and the development of cardiovascular diseases. ROS also activate the NLRP3 inflammasome, a protein complex involved in the activation of pro-inflammatory cytokines [18]. Upon activation by oxidative stress, NLRP3 inflammasomes induce the maturation and release of IL-1 $\beta$  and IL-18, further promoting inflammation and metabolic dysregulation [19]. In adipose tissue, oxidative stress and the subsequent activation of NF- $\kappa$ B and inflammasomes lead to the production of inflammatory adipokines, such as leptin, resistin, and visfatin, which exacerbate insulin resistance and contribute to systemic inflammation [20]. This chronic inflammatory environment, driven by oxidative stress, creates a cascade of metabolic disturbances. Inflammation further impairs insulin signaling, alters lipid metabolism, and increases the risk of endothelial dysfunction, all of which contribute to the development and progression of MetS [21].

#### **Endothelial Dysfunction and Oxidative Stress**

Endothelial dysfunction is a critical early event in the pathogenesis of atherosclerosis and cardiovascular disease, both of which are strongly associated with MetS [22]. The endothelium plays a vital role in regulating vascular tone, inflammation, and blood coagulation. One of the primary mechanisms by which oxidative stress contributes to endothelial dysfunction is through the reduction of nitric oxide (NO) bioavailability [23]. NO is a vasodilator produced by endothelial cells that helps maintain vascular tone and prevents platelet aggregation [23]. Under

normal conditions, NO is produced in response to endothelial shear stress, and it helps regulate blood flow and prevent vascular inflammation [24]. However, when ROS are generated in excess, they rapidly react with NO to form peroxynitrite (ONOO<sup>-</sup>), a highly reactive molecule that further impairs endothelial function [24]. This reduces the bioavailability of NO, leading to endothelial dysfunction, increased vascular resistance, and the promotion of atherosclerotic plaque formation. In addition to reducing NO availability, ROS activate several adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), which facilitate the recruitment of inflammatory cells to the endothelial surface [25]. This results in chronic inflammation of the blood vessels, further promoting the development of atherosclerosis and cardiovascular disease in individuals with MetS. The impairment of endothelial function is one of the earliest manifestations of MetS, which increases the risk of heart attacks, strokes, and other cardiovascular events [26].

### **Adiposity and Oxidative Stress**

Obesity, particularly central (visceral) obesity, is a major risk factor for MetS [27]. Excess fat accumulation, especially in the abdominal area, leads to the overproduction of ROS in adipocytes (fat cells) [28]. This is due to the increased metabolic activity of fat tissue, which results in an enhanced generation of ROS, particularly in the mitochondria [29]. ROS produced in adipocytes contribute to adipocyte dysfunction, leading to the dysregulation of fat metabolism and further fat accumulation [30]. In response to oxidative stress, adipocytes secrete pro-inflammatory cytokines and adipokines that exacerbate systemic inflammation and insulin resistance [31]. These inflammatory mediators, such as TNF- $\alpha$  and IL-6, are known to impair insulin signaling and contribute to the development of obesity-related insulin resistance [32]. Moreover, oxidative stress induces the apoptosis (programmed cell death) of adipocytes, leading to dysfunctional fat tissue that exacerbates the metabolic abnormalities seen in MetS [25].

ROS also play a significant role in lipid metabolism. Increased ROS production leads to altered lipid profiles, including elevated levels of triglycerides and low-density lipoprotein (LDL) cholesterol, which are characteristic of MetS [33]. These dyslipidemic changes increase the risk of atherosclerosis and other cardiovascular complications. Additionally, ROS promote the accumulation of lipids in non-adipose tissues, such as the liver and muscle, which contributes to ectopic fat deposition and insulin resistance [34].

### **Therapeutic Targeting of Oxidative Stress in Metabolic Syndrome**

Given the central role of oxidative stress in the pathophysiology of metabolic syndrome (MetS), targeting oxidative stress has emerged as a promising therapeutic strategy. Several approaches, including the use of antioxidants, pharmacological agents, and lifestyle interventions, have been proposed to mitigate oxidative stress and improve the metabolic disturbances associated with MetS. While antioxidants and other therapies show promise, challenges remain regarding their optimal use, safety, and efficacy in clinical practice [35, 36, 37, 38, 39].

#### **Antioxidant Therapies**

Antioxidant therapies are one of the most widely investigated approaches for mitigating oxidative stress in MetS. Natural antioxidants, such as polyphenols, flavonoids, and vitamins, have shown potential in reducing ROS levels, improving insulin sensitivity, and decreasing inflammation [40, 41, 42, 43, 44]. Compounds like resveratrol (found in red wine), curcumin (from turmeric), quercetin (a flavonoid in apples and onions), and green tea polyphenols (EGCG) have demonstrated antioxidant and anti-inflammatory effects that can reduce oxidative stress and alleviate symptoms of MetS [45, 46, 47, 48]. Clinical studies have shown that resveratrol supplementation can improve insulin sensitivity, reduce blood glucose levels, and enhance endothelial function in individuals with MetS [49, 50, 51, 52]. Similarly, curcumin has demonstrated anti-inflammatory and antioxidant effects, improving glucose metabolism and reducing lipid levels [53, 54, 55, 56, 57]. However, despite promising preclinical and small-scale clinical findings, the clinical efficacy of these antioxidants is often inconsistent, and there is a need for larger, well-controlled trials to establish the most effective dosages and treatment regimens.

Pharmacological antioxidants such as N-acetylcysteine (NAC) and alpha-lipoic acid (ALA) have also been investigated for their potential to reduce oxidative stress in MetS [39]. NAC works by replenishing glutathione, a major intracellular antioxidant, while ALA helps regenerate other antioxidants [58, 59, 60]. Both compounds have shown potential in improving insulin resistance and reducing inflammation in MetS patients, though their long-term safety and efficacy require further investigation.

#### **Lifestyle Interventions**

Lifestyle modifications remain a cornerstone in managing oxidative stress and MetS. Regular physical activity, weight loss, and a diet rich in antioxidant-rich foods (e.g., fruits, vegetables, nuts) can reduce oxidative damage and

enhance the body's antioxidant defenses. Exercise has been shown to increase the activity of endogenous antioxidant enzymes, improve insulin sensitivity, and reduce systemic inflammation [41]. Diets rich in omega-3 fatty acids, fiber, and polyphenols further support antioxidant capacity and reduce the risk of developing MetS [42]. Incorporating both antioxidant supplementation and lifestyle interventions can provide a holistic approach to managing oxidative stress and MetS, but careful monitoring and individualized treatment plans are essential for optimal outcomes.

## CONCLUSION

Oxidative stress plays a central role in the pathophysiology of metabolic syndrome by contributing to insulin resistance, inflammation, endothelial dysfunction, and dyslipidemia. While therapeutic strategies targeting oxidative stress, including antioxidant supplementation and lifestyle modifications, hold promise, more research is needed to establish their efficacy and safety in clinical practice. A comprehensive approach combining pharmacological interventions with lifestyle changes may offer the most effective strategy for managing oxidative stress in MetS and reducing the associated cardiovascular and metabolic risks.

## REFERENCES

1. Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. *Therapeutic Advances in Cardiovascular Disease*. 2017;11(8):215–25. doi:10.1177/1753944717711379
2. Masenga SK, Kabwe LS, Chakulya M, Kirabo A. Mechanisms of oxidative stress in metabolic syndrome. *International Journal of Molecular Sciences*. 2023;24(9):7898. doi:10.3390/ijms24097898
3. Ugwu, O.P.C., Kungu, E., Inyangat, R., Obeagu, E. I., Alum, E. U., Okon, M. B., Subbarayan, S. and Sankarapandian, V. Exploring Indigenous Medicinal Plants for Managing Diabetes Mellitus in Uganda: Ethnobotanical Insights, Pharmacotherapeutic Strategies, and National Development Alignment. *INOSR Experimental Sciences*. 2023; 12(2):214–224. <https://doi.org/10.59298/INOSRES/2023/2.17.1000>.
4. Alum, E. U., Ibiam, U. A., Ugwuja, E. I., Aja, P. M., Igwenyi, I. O., Offor, C. E., Orji, O. U., Ezeani N. N., Ugwu, O. P. C., Aloke, C., Egwu, C. O. Antioxidant Effect of *Buchholzia coriacea* Ethanol Leaf Extract and Fractions on Freund's Adjuvant-induced Arthritis in Albino Rats: A Comparative Study. *Slovenian Veterinary Research*. 2022; 59 (1): 31–45. doi: 10.26873/svr-1150-2022.
5. Ogbodo John Onyebuchi, Chinazom Precious Agbo, Ugoci Olivia Njoku, Martins Obinna Ogugofor, Egba Simeon Ikechukwu, Stella Amarachi Ihim, Adaeze Chidiebere Echezona Kenneth Chibuike Brendan, Aman Babanrao Upaganlawar, and Chandrashekar Devidas Upasani. Alzheimer's Disease: Pathogenesis and Therapeutic Interventions, *Current Aging Science*, 2021; 21:1–25.
6. Spahis S, Borys JM, Levy E. Metabolic syndrome as a multifaceted risk factor for oxidative stress. *Antioxidants and Redox Signaling*. 2016;26(9):445–61. doi:10.1089/ars.2016.6756
7. Swarup S, Ahmed I, Grigorova Y, Zeltser R. Metabolic syndrome. *StatPearls – NCBI Bookshelf*. 2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK459248/>
8. Afzal S, Manap ASA, Attiq A, Albokhadaim I, Kandeel M, Alhojaily SM. From imbalance to impairment: the central role of reactive oxygen species in oxidative stress-induced disorders and therapeutic exploration. *Frontiers in Pharmacology*. 2023;14. doi:10.3389/fphar.2023.1269581
9. Uroko Robert Ikechukwu., Agbafor Amarachi, Uchenna Oluomachi Nancy, Achi Ngozi Kalu, Egba Simeon Ikechukwu, Nweje-Anyalowu Paul Chukwuemaka and Ngwu Ogochukwu Rita. Evaluation of Antioxidant Activity of Aqueous Extracts of Palm Friuts (*Elaeis guineensis*) *Asian Journal of Biochemistry*, 2017; 12: 49–57
10. Besse-Patin A, Estall JL. An Intimate Relationship between ROS and Insulin Signalling: Implications for Antioxidant Treatment of Fatty Liver Disease. *International Journal of Cell Biology*. 2014;2014:1–9. doi:10.1155/2014/519153
11. Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. *Free Radical Biology and Medicine*. 2010;50(5):567–75. doi:10.1016/j.freeradbiomed.2010.12.006
12. De Meyts P. The insulin receptor and its signal transduction network. *Endotext – NCBI Bookshelf*. 2016. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK378978/>
13. Taniyama Y, Hitomi H, Shah A, Alexander RW, Griendling KK. Mechanisms of Reactive Oxygen Species–Dependent downregulation of insulin receptor substrate-1 by angiotensin II. *Arteriosclerosis Thrombosis and Vascular Biology*. 2005;25(6):1142–7. doi:10.1161/01.atv.0000164313.17167.df



14. Chen Y, Meng Z, Li Y, Liu S, Hu P, Luo E. Advanced glycation end products and reactive oxygen species: uncovering the potential role of ferroptosis in diabetic complications. *Molecular Medicine*. 2024;30(1). doi:10.1186/s10020-024-00905-9
15. Zhou M, Zhang Y, Shi L, Li L, Zhang D, Gong Z, et al. Activation and modulation of the AGEs-RAGE axis: Implications for inflammatory pathologies and therapeutic interventions – A review. *Pharmacological Research*. 2024;206:107282. doi:10.1016/j.phrs.2024.107282
16. Lingappan K. NF-κB in oxidative stress. *Current Opinion in Toxicology*. 2017;7:81–6. doi:10.1016/j.cotox.2017.11.002
17. Ogugua, Victor N., Njoku, Obioma U., Egba, Simeon I., Uroko, Robert I and Ignatius Glory. In vitro study of nutritional and antioxidant properties of methanol extract of *Nauclea latifolia* root bark. *Biomedical Research*, 2018; 29(21): 3766-3773
18. Abais JM, Xia M, Zhang Y, Boini KM, Li PL. Redox Regulation of NLRP3 Inflammasomes: ROS as trigger or Effector? Antioxidants and Redox Signaling. 2014;22(13):1111–29. doi:10.1089/ars.2014.5994
19. Moustakli E, Stavros S, Katopodis P, Skentou C, Potiris A, Panagopoulos P, et al. Oxidative stress and the NLRP3 inflammasome: Focus on female fertility and reproductive health. *Cells*. 2025;14(1):36. doi:10.3390/cells14010036
20. Varra FN, Varras M, Varra VK, Theodosios-Nobelos P. Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation-mediating treatment options (Review). *Molecular Medicine Reports*. 2024;29(6). doi:10.3892/mmr.2024.13219
21. Freeman AM, Acevedo LA, Pennings N. Insulin resistance. StatPearls – NCBI Bookshelf. 2023. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK507839/>
22. Das D, Shruthi NR, Banerjee A, Jothimani G, Duttaroy AK, Pathak S. Endothelial dysfunction, platelet hyperactivity, hypertension, and the metabolic syndrome: molecular insights and combating strategies. *Frontiers in Nutrition*. 2023;10. doi:10.3389/fnut.2023.1221438
23. Rodrigo R, González J, Paoletto F. The role of oxidative stress in the pathophysiology of hypertension. *Hypertension Research*. 2011;34(4):431–40. doi:10.1038/hr.2010.264
24. Lubos E. Role of oxidative stress and nitric oxide in atherothrombosis. *Frontiers in Bioscience*. 2008;13:5323. doi:10.2741/3084
25. Ugwu, CE., Sure, SM., Dike, CC., Okpoga, NA and Egba, SI. Phytochemical and *in vitro* antioxidant activities of methanol leave extract of *Alternanthera basiliiana*. *Journal of Pharmacy Research*, 2018; 12(6): 835-839
26. Suzuki T, Hirata K, Elkind MSV, Jin Z, Rundek T, Miyake Y, et al. Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: The Northern Manhattan Study (NOMAS). *American Heart Journal*. 2008;156(2):405–10. doi:10.1016/j.ahj.2008.02.022.
27. Alum, E. U. Metabolic memory in obesity: Can early-life interventions reverse lifelong risks? *Obesity Medicine*. 2025; 55,100610. <https://doi.org/10.1016/j.obmed.2025.100610>
28. Uti, D. E., Atangwho, I. J., Omang, W. A., Alum, E. U., Obeten, U. N., Udeozor, P.A., Agada, S. A., Bawa, I., Ogbu, C. O. Cytokines as key players in obesity low grade inflammation and related complications. *Obesity Medicine*, Volume 54, 2025,100585. <https://doi.org/10.1016/j.obmed.2025.100585>.
29. Naryzhnaya NV, Koshelskaya OA, Kologrivova IV, Suslova TE, Kharitonova OA, Andreev SL, et al. Production of Reactive Oxygen Species by Epicardial Adipocytes Is Associated with an Increase in Postprandial Glycemia, Postprandial Insulin, and a Decrease in Serum Adiponectin in Patients with Severe Coronary Atherosclerosis. *Biomedicines*. 2022;10(8):2054. doi:10.3390/biomedicines10082054
30. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. *Journal of Clinical Investigation*. 2004;114(12):1752–61. doi:10.1172/jci21625
31. Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. *Biomedicine & Pharmacotherapy*. 2021;137:111315. doi:10.1016/j.biopha.2021.111315
32. Kern L, Mittenbühler M, Vesting A, Ostermann A, Wunderlich C, Wunderlich F. Obesity-Induced TNFα and IL-6 Signaling: The Missing Link between Obesity and Inflammation—Driven Liver and Colorectal Cancers. *Cancers*. 2018;11(1):24. doi:10.3390/cancers11010024

33. Mohamed SM, Shalaby MA, El-Shiekh RA, El-Banna HA, Emam SR, Bakr AF. Metabolic syndrome: risk factors, diagnosis, pathogenesis, and management with natural approaches. Food Chemistry Advances. 2023;3:100335. doi:10.1016/j.focha.2023.100335
34. Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomedicine & Pharmacotherapy. 2021;137:111315. doi:10.1016/j.biopha.2021.111315
35. Ogugua, V N., Egba, S I., Anaduaka, E. G and Ozioko B O. Phytochemical analysis, anti-hyperglycaemic and anti-oxidant effect of the aqueous extracts of *Chromolaena odorata* on alloxan induced diabetic Rats. *Pharmanest*, 2013; 4(5): 970-977
36. Cione E, La Torre C, Cannataro R, Caroleo MC, Plastina P, Gallelli L. Quercetin, epigallocatechin gallate, curcumin, and resveratrol: from dietary sources to human MicroRNA modulation. Molecules. 2019;25(1):63. doi:10.3390/molecules25010063
37. Zhu X, Wu C, Qiu S, Yuan X, Li L. Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis. Nutrition & Metabolism. 2017;14(1). doi:10.1186/s12986-017-0217-z
38. Cheng M, Ding F, Li L, Dai C, Sun X, Xu J, et al. Exploring the role of curcumin in mitigating oxidative stress to alleviate lipid metabolism disorders. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1517174
39. Cheng M, Ding F, Li L, Dai C, Sun X, Xu J, et al. Exploring the role of curcumin in mitigating oxidative stress to alleviate lipid metabolism disorders. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1517174
40. Youssef FM, Elmokadem EM, Samy AEH, Ateyya H. Antioxidants as adjuvant therapy in the treatment of community-acquired pneumonia. Future Journal of Pharmaceutical Sciences. 2024;10(1). doi:10.1186/s43094-024-00674-6
41. Tkaczenko H, Kurhaluk N. Antioxidant-Rich functional foods and exercise: unlocking metabolic health through NRF2 and related pathways. International Journal of Molecular Sciences. 2025;26(3):1098. doi:10.3390/ijms26031098
42. Poudyal H, Panchal SK, Diwan V, Brown L. Omega-3 fatty acids and metabolic syndrome: Effects and emerging mechanisms of action. Progress in Lipid Research. 2011;50(4):372-87. doi:10.1016/j.plipres.2011.06.003
43. Orji OU, Ibiam UA, Aja PM, Ugwu P, Uraku AJ, Aloke C, Obasi OD, Nwali BU. Evaluation of the phytochemical and nutritional profiles of *Cnidioscolus aconitifolius* leaf collected in Abakaliki South East Nigeria. World J Med Sci. 2016;13(3):213-217.
44. Enechi OC, Okpe CC, Ibe GN, Omeje KO, Ugwu Okechukwu PC. Effect of *Buchholzia coriacea* methanol extract on haematological indices and liver function parameters in *Plasmodium berghei*-infected mice. Glob Veterinaria. 2016;16(1):57-66.
45. Alum EU, Uti DE, Ugwu Okechukwu PC, Alum BN. Toward a cure—Advancing HIV/AIDS treatment modalities beyond antiretroviral therapy: A review. Med. 2024;103(27):e38768.
46. Obeagu EI, Bot YS, Obeagu GU, Alum EU, Ugwu Okechukwu PC. Anaemia and risk factors in lactating mothers: A concern in Africa. Int J Innov Appl Res. 2024;11(2):15-17.
47. Alum EU, Ibiam UA, Ugwuja EI, Aja PM, Igwenyi IO, Offor CE, Orji UO, Ezeani NN, Ugwu OP, Aloke C, Egwu CO. Antioxidant effect of *Buchholzia coriacea* ethanol leaf extract and fractions on Freund's adjuvant-induced arthritis in albino rats: A comparative study. 2022;59(1):31-45.
48. Offor CE, Ugwu Okechukwu PC, Alum EU. Determination of ascorbic acid contents of fruits and vegetables. Int J Pharm Med Sci. 2015;5:1-3.
49. Amusa MO, Adepoju AO, Ugwu Okechukwu PC, Alum EU, Obeagu EI, Okon MB, Aja PM, Samson AOS. Effect of ethanol leaf extract of *Chromolaena odorata* on lipid profile of streptozotocin-induced diabetic Wistar albino rats. IAA J Biol Sci. 2024;10(1):109-117.
50. Amusa MO, Adepoju AO, Ugwu Okechukwu PC, Alum EU, Obeagu EI, Okon MB, Aja PM, Samson AOS. Effect of ethanol leaf extract of *Chromolaena odorata* on lipid profile of streptozotocin-induced diabetic Wistar albino rats. IAA J Biol Sci. 2024;10(1):109-117.
51. Enechi YS, Ugwu OC, Ugwu Okechukwu PC, Omeh K. Evaluation of the antinutrient levels of *Ceiba pentandra* leaves. IJRRPAS. 2013;3(3):394-400.
52. Ugwu Okechukwu PC, Nwodo OFC, Joshua EP, Odo CE, Ossai EC. Effect of ethanol leaf extract of *Moringa oleifera* on lipid profile of malaria-infected mice. Res J Pharm Biol Chem Sci. 2014;4(1):1324-1332.

53. Ugwu OPC, Alum EU, Uhama KC. Dual burden of diabetes mellitus and malaria: Exploring the role of phytochemicals and vitamins in disease management. *Res Inven J Res Med Sci*. 2024;3(2):38-49.
54. Alum EU, Ugwu Okechukwu PC, Aja PM, Obeagu EI, Inya JE, Onyeije AP, Agu E, Awuchi CG. Restorative effects of ethanolic leaf extract of *Datura stramonium* against methotrexate-induced hematological impairments. *Cogent Food Agric*. 2013;9(1):2258774.
55. Offor CE, Nwankwegu FC, Joshua EP, Ugwu Okechukwu PC. Acute toxicity investigation and anti-diarrhoeal effect of the chloroform-methanol extract of the leaves of *Persea americana*. *Iran J Pharm Res*. 2014;13(2):651-658. PMID: 25237361; PMCID: PMC4157041.
56. Afiukwa CA, Oko AO, Afiukwa JN, Ugwu Okechukwu PC, Ali FU, Ossai EC. Proximate and mineral element compositions of five edible wild grown mushroom species in Abakaliki, southeast Nigeria. *Res J Pharm Biol Chem Sci*. 2013;4:1056-1064.
57. Ugwu OP, Alum EU, Ugwu JN, Eze VH, Ugwu CN, Ogenyi FC, Okon MB. Harnessing technology for infectious disease response in conflict zones: Challenges, innovations, and policy implications. *Med*. 2024;103(28):e38834.
58. Obeagu EI, Ugwu OPC, Alum EU. Poor glycaemic control among diabetic patients; A review on associated factors. *Newport Int J Res Med Sci (NIJRMS)*. 2023;3(1):30-33.
59. Nwaka AC, Ikechi-Agba MC, Okechukwu PU, Igwenyi IO, Agbafor KN, Orji OU, Ezugwu AL. The effects of ethanol extracts of *Jatropha curcas* on some hematological parameters of chloroform intoxicated rats. *Am-Eur J Sci Res*. 2015;10(1):45-49.
60. Ezeani NN, Ibiam UA, Orji OU, Igwenyi IO, Alope C, Alum E, Aja PM, Ugwu OP. Effects of aqueous and ethanol root extracts of *Olax subscopioidea* on inflammatory parameters in complete Freund's adjuvant-collagen type II induced arthritic albino rats. *Pharmacogn J*. 2019;11(1)

**CITE AS: Mugisha Byaruhanga P. (2025). Exploring the Role of Oxidative Stress in the Pathophysiology of Metabolic Syndrome: Implications for Therapeutic Targeting. RESEARCH INVENTION JOURNAL OF RESEARCH IN MEDICAL SCIENCES 4(3):26-32.**  
<https://doi.org/10.59298/RIJRMS/2025/432632>